Twenty-two patients were included (77% female; median age 60 years). Sixty-four percent had sensitizing EGFR mutations, and 32% had an atypical EGFR mutation. Thirteen of the 22 patients (59%) were ...
Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022 Effective diagnosis, prognostication, ...
St. Louis, Nov. 15, 2005 -- A combination of brain scanning with a new imaging agent and cerebrospinal fluid (CSF) analysis has left neuroscientists encouraged that they may finally be moving toward ...
In the Alzheimer’s field, conventional wisdom holds that the growth of amyloid plaques in the brain soaks up Aβ42 peptide, depleting it from cerebrospinal fluid. Now, in the February 12 Nature Aging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results